The purpose of this manuscript is to offer an overview on the most prognostic factors affecting the clinical outcomes of patients with AML harboring CBFB-MYH11, with a special focus on the role of MRD monitoring in risk stratification and treatment guidance. The gene discussed is CBFB; the disease is acute myeloid leukemia.